MARK2

MARK2 (Microtubule Affinity-Regulating Kinase 2) is a serine/threonine kinase that modulates microtubule dynamics by phosphorylating microtubule-associated proteins (MAPs), thereby regulating cytoskeletal organization and cellular polarity^[1][2]. Mechanistically, MARK2 phosphorylates specific sites within MAPs, including tau, which reduces microtubule binding and facilitates microtubule remodeling^[3][1]. MARK2 activity influences multiple signaling pathways such as Hippo, mTOR, and NF-κB, connecting cytoskeletal regulation to cell proliferation, apoptosis, and intracellular transport^[2]. In disease models, MARK2 dysregulation contributes to neurodegenerative conditions through tau hyperphosphorylation and is implicated in cancer progression via modulation of cell cycle and survival pathways^[2]. Compared with related isoforms MARK1 and MARK4, MARK2 exhibits distinct substrate specificity and tissue expression patterns, enabling selective investigation of its cellular roles^[1][2]. For experimental applications, selective inhibitors of MARK2 have been identified, including low-micromolar compounds based on 9-oxo-9H-acridin-10-yl scaffolds, which allow precise modulation of kinase activity in neuronal and cancer cell models^[1]. These inhibitors are instrumental in studying microtubule dynamics, axon growth, and signal transduction with isoform-specific resolution^[1]. MARK2 thus serves as a critical target for understanding cytoskeletal regulation in health and disease and for the development of kinase-targeted interventions^[2].